RightFit Trial Directory

Lung Cancer clinical trials in Lexington, KY

22 recruiting lung cancer studies with a site in Lexington, KY.

All trials in Lexington, KY · All Lung Cancer trials

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Bardstown, KY · Corbin, KY · +1147 more sites

RecruitingPhase 2NCT06731907

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

Sponsor: Merck Sharp & Dohme LLC

Lexington, KY · +4 more sites

RecruitingPhase 2 / Phase 3NCT06712316

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

Sponsor: BioNTech SE

Elizabethtown, KY · Lexington, KY · +50 more sites

RecruitingPhase 2NCT07770100

Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

Sponsor: Mark Bernard

Lexington, KY

RecruitingPhase 2NCT06031688

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Sponsor: SWOG Cancer Research Network

Lexington, KY · +277 more sites

RecruitingPhase 3NCT06119581

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Sponsor: Eli Lilly and Company

Lexington, KY · +86 more sites

RecruitingPhase 2NCT06780098

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

Sponsor: Merck Sharp & Dohme LLC

Lexington, KY · +3 more sites

RecruitingPhase 3NCT07361497

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Sponsor: Bristol-Myers Squibb

Lexington, KY · +37 more sites

RecruitingPhase 3NCT06561386

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Sponsor: Bristol-Myers Squibb

Edgewood, KY · Lexington, KY · Paducah, KY · +53 more sites

RecruitingPhase 2 / Phase 3NCT07063745

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Sponsor: Bristol-Myers Squibb

Lexington, KY · +42 more sites

RecruitingPhase 3NCT06767514

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Sponsor: Summit Therapeutics

Lexington, KY · +96 more sites

RecruitingPhase 2NCT07459634

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Sponsor: Jazz Pharmaceuticals

Lexington, KY · +4 more sites

RecruitingPhase 1 / Phase 2NCT04486833

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Sponsor: Genprex, Inc.

Lexington, KY · +9 more sites

RecruitingPhase 1 / Phase 2NCT07564401

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

Sponsor: Novartis Pharmaceuticals

Lexington, KY · +2 more sites

RecruitingPhase 1 / Phase 2NCT04165070

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Sponsor: Merck Sharp & Dohme LLC

Lexington, KY · +17 more sites

RecruitingPhase 3NCT06203210

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Sponsor: Daiichi Sankyo

Lexington, KY · +29 more sites

RecruitingPhase 1NCT05283330

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Sponsor: Orano Med Theranostics, SAS

Lexington, KY · +7 more sites

RecruitingPhase 2NCT05642572

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Sponsor: SWOG Cancer Research Network

Bardstown, KY · Corbin, KY · Lexington, KY · +451 more sites

RecruitingPhase 2 / Phase 3NCT03851445

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Sponsor: SWOG Cancer Research Network

Ashland, KY · Bardstown, KY · Corbin, KY · +1226 more sites

RecruitingPhase 3NCT02468024

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

Sponsor: University of Texas Southwestern Medical Center

Lexington, KY · Louisville, KY · +38 more sites

RecruitingPhase 2NCT06769126

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Sponsor: SWOG Cancer Research Network

Corbin, KY · Lexington, KY · +145 more sites

Not yet recruitingPhase 1 / Phase 2NCT07707895

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

Sponsor: Boehringer Ingelheim

Lexington, KY · +3 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.